New Copaxone® (glatiramer acetate) formulation launched in UK
Posted in News Review on 14th Aug 2015
Teva UK Limited (“Teva”) has launched Copaxone® 40mg/ml three-times weekly injection. Copaxone® 20mg/ml is currently approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). With this new formulation, patients will only have to inject themselves three times per week – compared to daily injections with the existing formulation.
Approval was granted in December 2014 and was based on the findings from Teva’s Phase III Glatiramer Acetate Low-Frequency Administration (GALA) study, which involved over 1,400 patients. Results demonstrated that patients dosed three-times weekly with Copaxone® 40 mg/ml experienced significantly reduced relapse rates compared to placebo at 12 months, with a safety and tolerability profile similar to that of Copaxone® 20mg/ml daily.
Dr Ewan Walters, Teva UK’s Medical Director, said: “Teva has been committed to the pursuit of MS research, and the development of Copaxone®, for more than 20 years. We are proud to be able to bring to patients in the UK the option of this new, three-times weekly Copaxone® 40 mg/ml formulation which we believe will offer patients and their healthcare professionals flexibility in choosing a dosing regimen that works best for them.”
Copaxone has been available in the UK since 2000. The three-times weekly 40 mg/ml formulation gives patients a convenient treatment option. Clinical studies have shown three-times weekly Copaxone® can maintain the benefits of relapse reduction of the once-a-day formulation, with 57 percent fewer injections.
ACNR 2015;15(3):31. Online 30 /07/15Download this Article